Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesPrepaid AssetsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Construction in Progress (2020 - 2022)

Historic Construction in Progress for Marker Therapeutics (MRKR) over the last 3 years, with Q1 2022 value amounting to $4.1 million.

  • Marker Therapeutics' Construction in Progress changed N/A to $4.1 million in Q1 2022 from the same period last year, while for Mar 2022 it was $4.1 million, marking a year-over-year change of. This contributed to the annual value of $2.2 million for FY2021, which is 6726.47% down from last year.
  • Marker Therapeutics' Construction in Progress amounted to $4.1 million in Q1 2022.
  • In the past 5 years, Marker Therapeutics' Construction in Progress ranged from a high of $6.8 million in Q4 2020 and a low of $2.2 million during Q3 2021
  • Its 3-year average for Construction in Progress is $3.8 million, with a median of $3.4 million in 2020.
  • Examining YoY changes over the last 5 years, Marker Therapeutics' Construction in Progress showed a top increase of 5217.39% in 2021 and a maximum decrease of 6726.47% in 2021.
  • Quarter analysis of 3 years shows Marker Therapeutics' Construction in Progress stood at $6.8 million in 2020, then tumbled by 67.26% to $2.2 million in 2021, then surged by 83.7% to $4.1 million in 2022.
  • Its Construction in Progress stands at $4.1 million for Q1 2022, versus $2.2 million for Q4 2021 and $2.2 million for Q3 2021.